Edgewise Therapeutics, Inc. (EWTX) Operating cash flow 2020–2025
Edgewise Therapeutics, Inc. (EWTX) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$143.8MFY2025 · since FY2020: -$14.6M → -$143.8M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$143.8M | -31.9% |
| FY2024 | -$109.0M | -18.6% |
| FY2023 | -$91.9M | -74.7% |
| FY2022 | -$52.6M | -57.1% |
| FY2021 | -$33.5M | -129.0% |
| FY2020 | -$14.6M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More EWTX financial trends
EWTX RevenueEWTX Net incomeEWTX Net marginEWTX Gross profitEWTX Gross marginEWTX Operating incomeEWTX Operating marginEWTX Free cash flowEWTX Capital expendituresEWTX Return on equityEWTX Stock buybacksEWTX Dividends paidEWTX Total assetsEWTX Total liabilitiesEWTX Shareholders’ equityEWTX overview →